Experience with 2-chlorodeoxyadenosine in previously untreated children with newly diagnosed acute myeloid leukemia and myelodysplastic diseases.

@article{Krance2001ExperienceW2,
  title={Experience with 2-chlorodeoxyadenosine in previously untreated children with newly diagnosed acute myeloid leukemia and myelodysplastic diseases.},
  author={Robert A. Krance and Craig A. Hurwitz and David R. Head and Susana C. Raimondi and Fred G Behm and Kristine R. Crews and Deo Kumar Srivastava and H A Mahmoud and Willaim Roberts and Xin Tong and Raymond L. Blakley and Raul C. Ribeiro},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2001},
  volume={19 11},
  pages={2804-11}
}
PURPOSE To develop more effective chemotherapy regimens for childhood acute myelogenous leukemia (AML). PATIENTS AND METHODS Between June 1991 and December 1996, we administered the nucleoside analog 2-chlorodeoxyadenosine (2-CDA) to 73 children with primary AML and 20 children with secondary AML or myelodysplastic syndrome (MDS). Patients received one or two 5-day courses of 2-CDA (8.9 mg/m(2)/d) given by continuous infusion. All patients then received one to three courses of daunomycin… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 35 extracted citations

POST: A framework for set-based association analysis in high-dimensional data

2017 IEEE International Conference on Bioinformatics and Biomedicine (BIBM) • 2017
View 2 Excerpts

Similar Papers

Loading similar papers…